JP2022512778A5 - - Google Patents
Info
- Publication number
- JP2022512778A5 JP2022512778A5 JP2021521765A JP2021521765A JP2022512778A5 JP 2022512778 A5 JP2022512778 A5 JP 2022512778A5 JP 2021521765 A JP2021521765 A JP 2021521765A JP 2021521765 A JP2021521765 A JP 2021521765A JP 2022512778 A5 JP2022512778 A5 JP 2022512778A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- acid sequence
- seq
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862753002P | 2018-10-30 | 2018-10-30 | |
| US62/753,002 | 2018-10-30 | ||
| US201862774006P | 2018-11-30 | 2018-11-30 | |
| US62/774,006 | 2018-11-30 | ||
| US201962807582P | 2019-02-19 | 2019-02-19 | |
| US62/807,582 | 2019-02-19 | ||
| PCT/US2019/058971 WO2020092654A1 (en) | 2018-10-30 | 2019-10-30 | Anti-cd45 antibodies and conjugates thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512778A JP2022512778A (ja) | 2022-02-07 |
| JP2022512778A5 true JP2022512778A5 (https=) | 2022-11-07 |
| JP7669269B2 JP7669269B2 (ja) | 2025-04-28 |
Family
ID=70463930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521765A Active JP7669269B2 (ja) | 2018-10-30 | 2019-10-30 | 抗－ｃｄ４５抗体及びそのコンジュゲート |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12291576B2 (https=) |
| EP (1) | EP3877416A4 (https=) |
| JP (1) | JP7669269B2 (https=) |
| CN (1) | CN113302203A (https=) |
| AU (1) | AU2019370367A1 (https=) |
| CA (1) | CA3117367A1 (https=) |
| WO (1) | WO2020092654A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200376135A1 (en) * | 2018-10-23 | 2020-12-03 | Magenta Therapeutics, Inc. | Fc silenced antibody drug conjugates (adcs) and uses thereof |
| WO2020092655A1 (en) * | 2018-10-30 | 2020-05-07 | Magenta Therapeutics, Inc. | Methods for allogeneic hematopoietic stem cell transplantation |
| WO2020146432A1 (en) * | 2019-01-07 | 2020-07-16 | Magenta Therapeutics, Inc. | Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy |
| JP7650819B2 (ja) * | 2019-04-24 | 2025-03-25 | ブイオーアール バイオファーマ インコーポレーテッド | 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用 |
| IL292628A (en) | 2019-11-01 | 2022-07-01 | Magenta Therapeutics Inc | Anti-cd45 antibody and conjugates accordingly |
| GB202015235D0 (en) * | 2020-09-25 | 2020-11-11 | Ucl Business Plc | Anti-CD45 antibodies and related therapeutics |
| GB202015226D0 (en) * | 2020-09-25 | 2020-11-11 | Adc Therapeutics S A | Pyrrol obenzodiazepine-antibody conugates and uses thereof |
| KR20230122618A (ko) | 2020-12-21 | 2023-08-22 | 알로젠 테라퓨틱스 인코포레이티드 | 프로테아제 활성화 cd45-게이트 car |
| AU2022422572A1 (en) | 2021-12-23 | 2024-06-06 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd45 for use in cell therapy |
| IL321599A (en) * | 2022-12-23 | 2025-08-01 | Cimeio Therapeutics Ag | Antibodies targeting cd45 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| KR20250065477A (ko) * | 2023-11-03 | 2025-05-13 | 고려대학교 산학협력단 | 작용기 기능이 제거된 Fab-arm 교환 방지 Fc 변이체들 |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN119874942B (zh) * | 2025-03-28 | 2025-09-26 | 核欣(苏州)医药科技有限公司 | 一种放射性蛋白偶联药物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2046835B1 (en) * | 2006-08-11 | 2011-10-26 | Schering Corporation | Antibodies to il-17a |
| UA118029C2 (uk) | 2013-04-29 | 2018-11-12 | Ф. Хоффманн-Ля Рош Аг | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування |
| EP3157634B1 (en) * | 2014-06-23 | 2018-12-12 | Bionomics, Inc. | Antibodies that bind lgr4 |
| CN108112254B (zh) * | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| GB201601073D0 (en) * | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| US10294294B2 (en) * | 2015-09-10 | 2019-05-21 | Albert Einstein College Of Medicine | Synthetic antibodies to BAX and uses thereof |
| WO2017155937A1 (en) * | 2016-03-07 | 2017-09-14 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
| CN109641051A (zh) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| AU2019366960A1 (en) | 2018-10-23 | 2021-05-27 | Regeneron Pharmaceuticals, Inc. | Fc silenced antibody drug conjugates (ADCs) and uses thereof |
| IL292628A (en) | 2019-11-01 | 2022-07-01 | Magenta Therapeutics Inc | Anti-cd45 antibody and conjugates accordingly |
-
2019
- 2019-10-30 EP EP19878736.8A patent/EP3877416A4/en active Pending
- 2019-10-30 WO PCT/US2019/058971 patent/WO2020092654A1/en not_active Ceased
- 2019-10-30 CN CN201980086905.6A patent/CN113302203A/zh active Pending
- 2019-10-30 CA CA3117367A patent/CA3117367A1/en active Pending
- 2019-10-30 AU AU2019370367A patent/AU2019370367A1/en not_active Abandoned
- 2019-10-30 JP JP2021521765A patent/JP7669269B2/ja active Active
-
2021
- 2021-04-29 US US17/244,856 patent/US12291576B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512778A5 (https=) | ||
| US20230242648A1 (en) | Antibodies to integrin avb6 and use of same to treat cancer | |
| ES2523915T3 (es) | Agentes de unión a la diana variantes y usos de los mismos | |
| US9828428B2 (en) | Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates | |
| JP2022506072A5 (https=) | ||
| JP6454269B2 (ja) | Ｃｄ３３抗体及び癌を処置するためのその使用 | |
| CN107880126B (zh) | 抗ntb-a抗体及相关组合物和方法 | |
| JP2024535637A (ja) | 抗体及びその薬物コンジュゲ－ト並びに用途 | |
| EP4087613A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| CN110240654A (zh) | 结合cd73的抗体-药物偶联物 | |
| CN111712520A (zh) | 磷脂酰肌醇聚糖3抗体及其偶联物 | |
| JP2025148380A (ja) | 抗体－薬物コンジュゲート及びそれらの使用 | |
| WO2024235130A9 (zh) | 多环化合物及其制备方法和用途 | |
| JP2026512687A (ja) | ヒト化ｌ１ｃａｍ抗体－薬物複合体 | |
| CN114828887B (zh) | 抗-αVβ6抗体和抗体-药物偶联物 | |
| WO2024235135A1 (zh) | 大环化合物及其制备方法和用途 | |
| WO2024235131A1 (zh) | 大环类药物偶联物及其制备方法和用途 | |
| WO2024236163A1 (en) | T cell receptor beta constant region 2 (trbc2) antibodies | |
| WO2024258967A1 (en) | Anti-cd5 antibodies and their uses | |
| HK1211035B (zh) | 針對整聯蛋白αvβ6的抗體和使用該抗體治療癌症 |